Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Drug Storage | 1 | 2021 | 125 | 0.83 | Why? |
| Drug Prescriptions | 2 | 2018 | 1062 | 0.78 | Why? |
| CCR5 Receptor Antagonists | 1 | 2018 | 66 | 0.71 | Why? |
| Critical Pathways | 2 | 2018 | 1587 | 0.69 | Why? |
| HIV Fusion Inhibitors | 1 | 2018 | 80 | 0.69 | Why? |
| Chickenpox Vaccine | 1 | 2018 | 59 | 0.68 | Why? |
| Otitis Media | 1 | 2018 | 106 | 0.67 | Why? |
| Treatment Failure | 2 | 2018 | 2106 | 0.58 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2018 | 282 | 0.56 | Why? |
| Chickenpox | 1 | 2018 | 194 | 0.56 | Why? |
| Rotavirus Vaccines | 3 | 2018 | 203 | 0.54 | Why? |
| Pharyngitis | 1 | 2018 | 687 | 0.53 | Why? |
| Rotavirus Infections | 3 | 2018 | 355 | 0.48 | Why? |
| Mass Vaccination | 1 | 2021 | 1101 | 0.42 | Why? |
| Anti-Bacterial Agents | 3 | 2018 | 10083 | 0.34 | Why? |
| Feces | 2 | 2020 | 4235 | 0.33 | Why? |
| Community-Acquired Infections | 1 | 2018 | 2328 | 0.29 | Why? |
| Infant | 15 | 2021 | 30274 | 0.28 | Why? |
| Rotavirus | 2 | 2018 | 329 | 0.27 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.25 | Why? |
| HIV Infections | 6 | 2020 | 11620 | 0.25 | Why? |
| Child | 24 | 2021 | 70012 | 0.25 | Why? |
| Gastroenteritis | 2 | 2017 | 489 | 0.24 | Why? |
| Child, Preschool | 12 | 2021 | 36283 | 0.23 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.21 | Why? |
| Hepatitis B | 2 | 2019 | 888 | 0.21 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.20 | Why? |
| Cold Temperature | 1 | 2021 | 260 | 0.20 | Why? |
| Food, Formulated | 1 | 2018 | 10 | 0.19 | Why? |
| Glucans | 1 | 2018 | 13 | 0.19 | Why? |
| Hepatitis C, Chronic | 2 | 2019 | 973 | 0.18 | Why? |
| Adolescent | 19 | 2021 | 86841 | 0.18 | Why? |
| Vaccines, Combined | 1 | 2018 | 67 | 0.18 | Why? |
| Oligosaccharides | 1 | 2018 | 69 | 0.18 | Why? |
| Italy | 8 | 2021 | 38444 | 0.17 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.17 | Why? |
| Streptococcus pyogenes | 1 | 2018 | 118 | 0.17 | Why? |
| Human papillomavirus 18 | 1 | 2017 | 36 | 0.17 | Why? |
| Infant Formula | 1 | 2018 | 64 | 0.17 | Why? |
| Neutralization Tests | 2 | 2021 | 6698 | 0.17 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.16 | Why? |
| Human papillomavirus 16 | 1 | 2017 | 95 | 0.16 | Why? |
| Rectum | 1 | 2020 | 495 | 0.16 | Why? |
| Receptors, CCR5 | 1 | 2018 | 186 | 0.16 | Why? |
| CD4 Lymphocyte Count | 2 | 2018 | 1517 | 0.15 | Why? |
| Infant, Newborn | 8 | 2021 | 23105 | 0.15 | Why? |
| Databases, Factual | 3 | 2018 | 6248 | 0.15 | Why? |
| Pediatricians | 1 | 2019 | 401 | 0.14 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.13 | Why? |
| Prenatal Exposure Delayed Effects | 1 | 2017 | 319 | 0.13 | Why? |
| Data Collection | 2 | 2021 | 1769 | 0.12 | Why? |
| Cluster Analysis | 1 | 2021 | 3001 | 0.12 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 451 | 0.12 | Why? |
| Antidepressive Agents | 1 | 2017 | 509 | 0.11 | Why? |
| Papillomavirus Vaccines | 1 | 2017 | 405 | 0.11 | Why? |
| Dermatitis, Atopic | 2 | 2018 | 714 | 0.11 | Why? |
| Pediatrics | 3 | 2020 | 2969 | 0.11 | Why? |
| Data Mining | 1 | 2017 | 767 | 0.10 | Why? |
| Antimicrobial Stewardship | 1 | 2018 | 931 | 0.10 | Why? |
| HIV-1 | 3 | 2018 | 3365 | 0.10 | Why? |
| Viral Tropism | 1 | 2018 | 1329 | 0.10 | Why? |
| Infectious Disease Transmission, Vertical | 4 | 2019 | 5164 | 0.10 | Why? |
| Registries | 3 | 2018 | 12327 | 0.10 | Why? |
| Cooperative Behavior | 1 | 2017 | 1216 | 0.10 | Why? |
| Europe | 7 | 2021 | 12702 | 0.10 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.10 | Why? |
| Humans | 34 | 2021 | 930598 | 0.09 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.09 | Why? |
| Pharmacoepidemiology | 1 | 2008 | 84 | 0.09 | Why? |
| Drug Utilization Review | 1 | 2008 | 72 | 0.09 | Why? |
| Symptom Assessment | 1 | 2021 | 4967 | 0.08 | Why? |
| Malaria | 1 | 2017 | 1097 | 0.08 | Why? |
| Hepatitis B Surface Antigens | 2 | 2019 | 305 | 0.08 | Why? |
| Medical Records Systems, Computerized | 1 | 2008 | 159 | 0.08 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.08 | Why? |
| Economics, Pharmaceutical | 1 | 2006 | 61 | 0.08 | Why? |
| Pregnancy Complications | 1 | 2017 | 1388 | 0.08 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.07 | Why? |
| Zika Virus Infection | 1 | 2019 | 1920 | 0.07 | Why? |
| Immunization Programs | 1 | 2018 | 2006 | 0.07 | Why? |
| Female | 19 | 2021 | 380317 | 0.07 | Why? |
| Outpatients | 1 | 2018 | 3417 | 0.07 | Why? |
| Emergency Service, Hospital | 2 | 2020 | 14232 | 0.07 | Why? |
| Gastrointestinal Microbiome | 1 | 2017 | 1961 | 0.07 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.07 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.06 | Why? |
| Male | 16 | 2021 | 367725 | 0.06 | Why? |
| Quality-Adjusted Life Years | 1 | 2006 | 511 | 0.06 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.06 | Why? |
| Alanine Transaminase | 2 | 2019 | 1329 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Inpatients | 1 | 2018 | 5161 | 0.06 | Why? |
| HIV Seropositivity | 1 | 2003 | 320 | 0.06 | Why? |
| Viral Load | 2 | 2021 | 15850 | 0.05 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.05 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.05 | Why? |
| Health Care Surveys | 2 | 2020 | 2942 | 0.05 | Why? |
| Phylogeny | 2 | 2017 | 13341 | 0.05 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.05 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Travel | 1 | 2017 | 7220 | 0.04 | Why? |
| Prebiotics | 1 | 2018 | 53 | 0.04 | Why? |
| Protein Subunits | 1 | 2021 | 755 | 0.04 | Why? |
| Mozambique | 1 | 2018 | 205 | 0.04 | Why? |
| Lipid A | 1 | 2017 | 32 | 0.04 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.04 | Why? |
| Uridine Monophosphate | 1 | 2017 | 41 | 0.04 | Why? |
| Aluminum Hydroxide | 1 | 2017 | 133 | 0.04 | Why? |
| Liver Cirrhosis | 2 | 2019 | 1810 | 0.04 | Why? |
| Microcephaly | 1 | 2019 | 181 | 0.04 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.04 | Why? |
| Elasticity Imaging Techniques | 1 | 2019 | 194 | 0.04 | Why? |
| Hepatitis B Vaccines | 1 | 2019 | 245 | 0.04 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 2 | 2019 | 11559 | 0.04 | Why? |
| B-Lymphocytes | 2 | 2021 | 4418 | 0.04 | Why? |
| Pregnancy | 4 | 2019 | 23879 | 0.04 | Why? |
| Serologic Tests | 2 | 2021 | 4359 | 0.04 | Why? |
| Adult | 7 | 2021 | 244371 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Cost of Illness | 1 | 2006 | 1903 | 0.04 | Why? |
| Harm Reduction | 1 | 2019 | 392 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Disease Transmission, Infectious | 1 | 2018 | 9044 | 0.03 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.03 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.03 | Why? |
| Antiviral Agents | 4 | 2019 | 41703 | 0.03 | Why? |
| Infant, Premature | 1 | 2018 | 883 | 0.03 | Why? |
| Chemoprevention | 1 | 2017 | 585 | 0.03 | Why? |
| Sofosbuvir | 1 | 2017 | 518 | 0.03 | Why? |
| Health Services Research | 1 | 2018 | 756 | 0.03 | Why? |
| Aspartate Aminotransferases | 1 | 2019 | 1394 | 0.03 | Why? |
| Retrospective Studies | 3 | 2018 | 105322 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2018 | 15909 | 0.03 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2019 | 1316 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.03 | Why? |
| Practice Guidelines as Topic | 3 | 2020 | 15421 | 0.03 | Why? |
| Proteome | 1 | 2021 | 1812 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Ribavirin | 1 | 2017 | 1182 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
| Hepacivirus | 1 | 2019 | 1509 | 0.02 | Why? |
| Pakistan | 1 | 2017 | 2302 | 0.02 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
| Carcinoma, Hepatocellular | 1 | 2019 | 1222 | 0.02 | Why? |
| Hospitals, Teaching | 1 | 2017 | 1609 | 0.02 | Why? |
| DNA, Viral | 1 | 2019 | 2521 | 0.02 | Why? |
| Case-Control Studies | 2 | 2017 | 17671 | 0.02 | Why? |
| Risk | 1 | 2020 | 5288 | 0.02 | Why? |
| Aged | 5 | 2021 | 215776 | 0.02 | Why? |
| Drug Therapy, Combination | 2 | 2017 | 7268 | 0.02 | Why? |
| Genotype | 1 | 2019 | 4697 | 0.02 | Why? |
| Liver Neoplasms | 1 | 2019 | 1666 | 0.02 | Why? |
| Vaccination | 2 | 2018 | 19050 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Depressive Disorder | 1 | 2017 | 1236 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4545 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2017 | 3567 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Dietary Supplements | 1 | 2018 | 2251 | 0.02 | Why? |
| Immunoassay | 1 | 2021 | 4485 | 0.02 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2018 | 3493 | 0.02 | Why? |
| Antimalarials | 1 | 2017 | 2505 | 0.02 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.02 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.02 | Why? |
| Signal Transduction | 1 | 2021 | 7207 | 0.02 | Why? |
| Interferon Type I | 1 | 2017 | 2789 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2019 | 10017 | 0.02 | Why? |
| Siblings | 1 | 2003 | 226 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.01 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Referral and Consultation | 1 | 2018 | 4816 | 0.01 | Why? |
| Brain | 1 | 2019 | 5133 | 0.01 | Why? |
| Triage | 1 | 2020 | 7151 | 0.01 | Why? |
| Hospitalization | 2 | 2018 | 54280 | 0.01 | Why? |
| Attitude of Health Personnel | 1 | 2019 | 4741 | 0.01 | Why? |
| Spain | 1 | 2019 | 15545 | 0.01 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2002 | 309 | 0.01 | Why? |
| Disease Progression | 1 | 2019 | 13580 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2019 | 7330 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.01 | Why? |
| Psychology | 1 | 2002 | 447 | 0.01 | Why? |
| Middle Aged | 3 | 2021 | 270681 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2021 | 88759 | 0.01 | Why? |
| Internet | 1 | 2008 | 6204 | 0.01 | Why? |
| Anti-HIV Agents | 1 | 2002 | 2209 | 0.01 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.01 | Why? |
| Mutation | 1 | 2003 | 12376 | 0.00 | Why? |
Giaquinto's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(203)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(102)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_